United States federal scheduling
Federal controlled-substance status remains central to any assessment of ibogaine activity. State-level bills or local discussions do not supersede federal scheduling.
Ibogaine News: Trials, Laws And Clinic Updates
Regulatory Tracker
A citation-first overview of formal laws, agency actions, trial records, and policy proposals affecting ibogaine and ibogaine-derived compounds.
Scope and method
Read the status before the headline.
This tracker distinguishes formal change from discussion. It follows national scheduling, enacted statutes, introduced bills, registered clinical studies, and statements from agencies such as the U.S. Food and Drug Administration. For broader context on the compound itself, the Kavora evidence-first overview places policy developments alongside research and safety questions.
Ibogaine remains a controlled substance in many jurisdictions. In the United States, its federal classification is listed in the DEA’s controlled-substance schedule materials; a bill, a registry entry, or an agency discussion does not by itself change that status.
ProposedA bill, draft rule, or public policy proposal without completed legal effect.
Active TrialA registered study or authorized investigational pathway; not an approval.
Approved/ChangedA documented enacted law, scheduling action, or formal regulatory decision.
UnchangedNo verified shift in the applicable national or federal status identified here.
National and federal status
Control status is jurisdiction-specific.
Ibogaine’s legal position cannot be inferred from activity in a neighboring country or from a private provider’s claims. The most durable starting point is the relevant statute, schedule, or ministry notice. A high-level background entry on ibogaine’s legal status across jurisdictions is useful for orientation, but current legal interpretation should rest on primary government material.
Unchanged — United States: federal scheduling remains the baseline regulatory fact. The FDA’s public materials on the Investigational New Drug application process explain why a research pathway and a marketing approval are different regulatory events.
Unchanged — international context: domestic controls may differ even where international drug-control frameworks are relevant. This page therefore treats national legislation and national agency statements as separate records rather than assuming a universal status.
Since 2020
A concise record of what changed—and what did not.
Research pathways
Clinical research should be checked against trial registries and sponsor disclosures. A study record is evidence of a research activity, not evidence that a therapy has been approved.
Legislative discussion
Introduced bills, task-force recommendations, and policy announcements are tracked as proposals unless an official enacted text or agency decision establishes a change.
Formal actions only
When a jurisdiction changes a schedule, authorizes a defined research route, or issues a binding notice, the record should identify the date, authority, and original document.
Trial records and agency actions
An IND is not a treatment authorization.
In the U.S., an IND may allow an investigational drug to be studied in people under defined conditions; it is not an approval for general marketing or routine treatment. Formal study entries can be checked through the ClinicalTrials.gov registry, where identifiers, recruitment status, and stated outcomes can be reviewed directly.
When a record references an ibogaine-derived compound, keep the compound name, sponsor, registry identifier, jurisdiction, and status distinct. Naming is not trivial: the terminology collected in ibogaine naming references can help readers notice when claims appear to merge related but legally distinct substances.
European regulatory developments should likewise be tied to an official source. The European Medicines Agency’s clinical-trials overview describes the regulatory framework rather than endorsing any specific investigational substance.
“A credible regulatory update names the authority, the date, the legal instrument, and the exact status—without turning a proposal into permission.”
That distinction is especially important where research activity, policy debate, and commercial language appear side by side.
How to read the tracker
Questions that keep the record clear.
What counts as a regulatory change?
A verified change has a named authority and an official legal or agency document. A legislative introduction remains Proposed until it is enacted or otherwise takes effect. For a broader explanation of how Kavora handles evidence and uncertainty, see the principles behind this independent resource.
Why are clinic claims not included?
This tracker does not assess clinics, availability, or individual care claims. Listings described as treatment centers near a reader do not establish national authorization, and a directory cannot replace a regulator’s own record.
How should cost information be interpreted?
Price information is outside this regulatory record. Discussions of the cost of ibogaine treatment should not be read as evidence of legal status, regulatory approval, or suitability.
What about international destination claims?
Country-specific statements require country-specific primary sources. Mentions of ibogaine clinics in Costa Rica or claims about a best ibogaine treatment clinic are not used here as proof of a regulatory position. Likewise, research discussion about ibogaine and Alzheimer’s or ibogaine and brain ageing remains separate from a formal authorization record.